Previous 10 | Next 10 |
Board A ppointments Designed to Position Company for Anticipated Milestones While Ensuring Adherence to the Highest Governance Standards HANOVER, MD, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage bioph...
Processa Pharmaceuticals, Inc. (PCSA) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants James Stanker - Chief Financial Officer David Young - President and Chief Executive Officer Conference Call Participants François B...
Processa Pharmaceuticals press release ( NASDAQ: PCSA ): Q2 GAAP EPS of $0.53 beats by $0.73 . Company cash balance on June 30, 2022, was $12.1 million, For further details see: Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73
PCS12852 on target to complete enrollment by September Expanded efforts to increase enrollment in PCS 499 and PCS 6422 showing results HANOVER, Md., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has scheduled a conference call and webcast to discuss its ...
HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a co...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has released a new website: Necrobiosislipoidicastudy.com. ...
HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet ...
HANOVER, MD, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet ...
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions, has announced that its CEO Dr. David Young will present at the World Orphan Drug Congress US...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...